Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43839   clinical trials with a EudraCT protocol, of which   7280   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites

    Summary
    EudraCT number
    2012-003390-26
    Trial protocol
    LV   GR   ES  
    Global end of trial date
    25 Sep 2013

    Results information
    Results version number
    v1(current)
    This version publication date
    29 Jul 2016
    First version publication date
    29 Jul 2016
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    BSG-12
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01657305
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Birken AG
    Sponsor organisation address
    Streiflingsweg 11, Niefern-Oeschelbronn, Germany, 75223
    Public contact
    Pharmaceutical Development, Birken AG, +49 723397490, info@birken.eu
    Scientific contact
    Pharmaceutical Development, Birken AG, +49 723397490, info@birken.eu
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Apr 2014
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    25 Sep 2013
    Global end of trial reached?
    Yes
    Global end of trial date
    25 Sep 2013
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To compare intra-individually the efficacy and tolerability of Oleogel-S10 versus non-adhesive wound dressing alone in accelerating the wound healing of Split-Thickness Skin Graft Donor Sites (STSG).
    Protection of trial subjects
    The study was conducted in compliance with the study protocol, ethical principles originating in or derived from the Declaration of Helsinki, ethics committee informed consent regulations, and International Council on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. In addition, all national and local regulatory requirements were followed. Insurance coverage for all participating subjects was guaranteed according to applicable legal requirements. Before undergoing any study-specific procedures, subjects were informed about the nature, scope, and possible consequences of the study. The investigator was responsible for obtaining a subject's written informed consent to participate in the study.
    Background therapy
    Non-adhesive wound dressing.
    Evidence for comparator
    Non-adhesive wound dressing represents a standard of care for patients with STSG donor sites.
    Actual start date of recruitment
    04 Apr 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 57
    Country: Number of subjects enrolled
    France: 11
    Country: Number of subjects enrolled
    Greece: 14
    Country: Number of subjects enrolled
    Latvia: 31
    Worldwide total number of subjects
    113
    EEA total number of subjects
    113
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    90
    From 65 to 84 years
    17
    85 years and over
    6

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Study participants were enrolled from 04-Apr-2013 to 26-Aug-2013 at 14 clinical centres in 4 countries: Spain (6 centres), Greece (3 centres), Latvia (2 centres), France (3 centres).

    Pre-assignment
    Screening details
    During screening the following was performed: informed consent, demographics, medical history, prior medication, and prenancy test. On day of surgery the inclusion/exclusion criteria were checked. 113 subjects were screened and enrolled, but only 112 subjects were treated since the STSG sugery was cancelled for one subject.

    Pre-assignment period milestones
    Number of subjects started
    113
    Number of subjects completed
    112

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    No treatment: 1
    Period 1
    Period 1 title
    Treatment period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Single blind
    Roles blinded
    Assessor [1]
    Blinding implementation details
    Treatments were intra-individually compared. The STSG donor site was divided into two areas of equal size. Since the distance of the wounds from the centre of the body might influence the wound healing process, the wound halves were randomly assigned to treatment by a temper-proof method. Treatment was open to study subjects and investigators, but assessment of efficacy was primarily based on blinded photo evaluation. Special care was taken to ensure blinding, i.e. all markings were removed.

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Oleogel-S10
    Arm description
    One half of the study wound was treated with Oleogel-S10 plus non-adhesive dressing.
    Arm type
    Experimental

    Investigational medicinal product name
    Oleogel-S10
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Ointment
    Routes of administration
    Topical use
    Dosage and administration details
    About 1 cm Oleogel-S10 ointment (approximately 100 mg) per cm² (i.e. approximately 1 mm thick) was applied at every wound dressing change (every 3 to 4 days) to one half of the STSG donor site by applying it onto the wound-facing side of the wound dressing.

    Arm title
    Standard of care
    Arm description
    One half of the study wound was treated according to standard of care by applying a non-adhesive dressing.
    Arm type
    In-active comparator

    Investigational medicinal product name
    Non-adhesive dressing
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Cutaneous patch
    Routes of administration
    Topical use
    Dosage and administration details
    The dressing was changed every 3 to 4 days.

    Notes
    [1] - The roles blinded appear inconsistent with a simple blinded trial.
    Justification: Treatment was open to study subjects and investigators, but assessment of efficacy was performed by assessors based on blinded photo evaluation.
    Number of subjects in period 1
    Oleogel-S10 Standard of care
    Started
    112
    112
    Completed
    92
    92
    Not completed
    20
    20
         Adverse events or other safety reasons
    5
    5
         Other
    2
    2
         No full wound closing achieved at Day 28
    13
    13

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups [1]
    Reporting group title
    Treatment period
    Reporting group description
    112 subjects treated had 224 wound halves that were compared.

    Notes
    [1] - The number of subjects reported to be in the baseline period is not equal to the worldwide number of subjects enrolled in the trial. It is expected that these numbers will be the same.
    Justification: 112 patients were randomised and received study treatment.
    Reporting group values
    Treatment period Total
    Number of subjects
    112 112
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    89 89
        From 65-84 years
    17 17
        85 years and over
    6 6
    Age continuous
    Units: years
        median (full range (min-max))
    49 (19 to 90) -
    Gender categorical
    Units: Subjects
        Female
    39 39
        Male
    73 73

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Oleogel-S10
    Reporting group description
    One half of the study wound was treated with Oleogel-S10 plus non-adhesive dressing.

    Reporting group title
    Standard of care
    Reporting group description
    One half of the study wound was treated according to standard of care by applying a non-adhesive dressing.

    Primary: Intra-individual difference in time to wound closure

    Close Top of page
    End point title
    Intra-individual difference in time to wound closure
    End point description
    The primary endpoint of this study was the intra-individual difference in time to wound closure (defined as at least 95% epithelialization) between wound halves either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing alone, based on blinded photo evaluation by three independent, blinded experts.
    End point type
    Primary
    End point timeframe
    Within 28 days after start of treatment (Day 0 - Day 28). Photos were aquired at every wound dressing change every 3 to 4 days.
    End point values
    Oleogel-S10 Standard of care
    Number of subjects analysed
    110
    110
    Units: day
        arithmetic mean (confidence interval 95%)
    -0.8 (-1.5 to -0.1)
    0 (0 to 0)
    Statistical analysis title
    Primary analysis
    Statistical analysis description
    The test was performed as a two-sided paired t-test at a significance level of 5% for the null-hypothesis of no difference δ = 0 against the hypotheses δ ≠ 0: H0: δ = 0; H1: δ ≠ 0;
    Comparison groups
    Oleogel-S10 v Standard of care
    Number of subjects included in analysis
    220
    Analysis specification
    Pre-specified
    Analysis type
    other [1]
    P-value
    = 0.0232 [2]
    Method
    Two-sided paired t-test
    Parameter type
    Mean difference (final values)
    Point estimate
    -0.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.5
         upper limit
    -0.1
    Variability estimate
    Standard deviation
    Dispersion value
    3.6
    Notes
    [1] - Difference in time to wound closure was calculated by comparing wound closure times of corresponding wound halves per patient followed by calculation of the mean of the expert-specific differences for each patient. The primary endpoint was then derived from the mean values for all subjects. If wound closure was not observed in a wound half (2 subjects), specific assumptions were made to calculate the difference e.g. wound closure later than the last photo, or intra-individual difference is 0.
    [2] - The p-value indicated above is valid for the intra-individual comparison of time to wound closure between the 2 wound halves for the Intention-To-Treat analysis set (110 subjects).

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events were recorded from start of study treatment to completion of study treatment.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    16.0
    Reporting groups
    Reporting group title
    Safety analysis set
    Reporting group description
    The safety analysis set (SAF) includes all patients who have been treated at least once, i.e. who received any dose of Oleogel-S10 or non-adhesive wound dressing. If the application of any treatment is not certain, the patient was included in the SAF. Within the SAF, the wound halves were analyzed ´as treated´.

    Serious adverse events
    Safety analysis set
    Total subjects affected by serious adverse events
         subjects affected / exposed
    5 / 112 (4.46%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Injury, poisoning and procedural complications
    Postoperative wound complication
    alternative assessment type: Systematic
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Bronchospasm
    alternative assessment type: Systematic
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Mania
    alternative assessment type: Systematic
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Bacteraemia
    alternative assessment type: Systematic
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Sepsis
    alternative assessment type: Systematic
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Wound infection
    alternative assessment type: Systematic
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Safety analysis set
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    60 / 112 (53.57%)
    Vascular disorders
    Haematoma
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Hypertension
         subjects affected / exposed
    4 / 112 (3.57%)
         occurrences all number
    4
    Hypotension
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Lymphoedema
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Thrombophlebitis superficial
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Surgical and medical procedures
    Removal of internal fixation
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    General disorders and administration site conditions
    Chills
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    3
    Feeling of body temperature change
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Infusion site extravasation
         subjects affected / exposed
    4 / 112 (3.57%)
         occurrences all number
    5
    Injection site reaction
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Mucosal induration
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Oedema peripheral
         subjects affected / exposed
    3 / 112 (2.68%)
         occurrences all number
    3
    Pain
         subjects affected / exposed
    6 / 112 (5.36%)
         occurrences all number
    6
    Pyrexia
         subjects affected / exposed
    12 / 112 (10.71%)
         occurrences all number
    13
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Dyspnoea
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Productive cough
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Insomnia
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Tobacco withdrawal symptoms
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Investigations
    Haematocrit decreased
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Transaminases increased
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Injury, poisoning and procedural complications
    Infusion related reaction
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Medication error
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Post procedural complication
         subjects affected / exposed
    5 / 112 (4.46%)
         occurrences all number
    5
    Post procedural haematoma
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Procedural pain
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Wound complication
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Wound dehiscence
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Wound haematoma
         subjects affected / exposed
    3 / 112 (2.68%)
         occurrences all number
    3
    Wound haemorrhage
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Wound secretion
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Myoclonus
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Somnolence
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Syncope
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    6 / 112 (5.36%)
         occurrences all number
    6
    Leukocytosis
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Thrombocytopenia
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Eye disorders
    Conjunctivitis
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Dry eye
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Eye pruritus
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Abdominal pain upper
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Constipation
         subjects affected / exposed
    8 / 112 (7.14%)
         occurrences all number
    8
    Diarrhoea
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Nausea
         subjects affected / exposed
    3 / 112 (2.68%)
         occurrences all number
    3
    Vomiting
         subjects affected / exposed
    3 / 112 (2.68%)
         occurrences all number
    3
    Skin and subcutaneous tissue disorders
    Dermatitis
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Ecchymosis
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Excessive granulation tissue
         subjects affected / exposed
    3 / 112 (2.68%)
         occurrences all number
    3
    Pain of skin
         subjects affected / exposed
    10 / 112 (8.93%)
         occurrences all number
    10
    Pruritus
         subjects affected / exposed
    9 / 112 (8.04%)
         occurrences all number
    9
    Skin burning sensation
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Urticaria
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Renal and urinary disorders
    Bladder dilatation
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Cystitis noninfective
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Pollakiuria
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Urinary retention
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1
    Infections and infestations
    Skin infection
         subjects affected / exposed
    9 / 112 (8.04%)
         occurrences all number
    9
    Urinary tract infection
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Wound infection
         subjects affected / exposed
    3 / 112 (2.68%)
         occurrences all number
    3
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    2 / 112 (1.79%)
         occurrences all number
    2
    Hyperkalaemia
         subjects affected / exposed
    1 / 112 (0.89%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    29 Jan 2013
    Main changes were: - In the secondary endpoint ‘Percentage of wound epithelialisation at different time points as assessed by....’, ’the investigator’ was changed to ‘study team member during wound dressing change’. - ‘Second or third’ day was changed to ‘third or fourth’ day for the interval of dressing change. - The number of sites was increased from 13 to 15. - In the inclusion criterion no. 2 the size of the wound area was reduced from 20 cm² to 15 cm². - In inclusion criterion no. 5, the phrase ’who are in the period between menarche and menopause’ was added to women of childbearing potential. - ‘Sexually active, non-vasectomized men must use a barrier method (condoms) during the treatment phase of this clinical trial’ was added to inclusion criterion no. 5.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA